COVID-19

Arcturus Therapeutics and CSL Report EMA’s Validation of MAA for ARCT-154 Vaccine to Prevent COVID-19

Arcturus Therapeutics and CSL Report EMA’s Validation of MAA for ARCT-154 Vaccine to Prevent COVID-19

Shots: The EMA has validated the MAA for ARCT-154, a next-generation mRNA vaccine...

Novavax’s Nuvaxovid Receives EC’s Marketing Authorization for the Prevention of COVID-19

Novavax’s Nuvaxovid Receives EC’s Marketing Authorization for the Prevention of COVID-19

Shots: The EC has granted full marketing authorization for Nuvaxovid (NVX-CoV2373)...

Merck’s Lagevrio (molnupiravir) Missed Primary Endpoints in P-III Trial (MOVe-AHEAD) for Post-Exposure Prophylaxis to Prevent COVID-19

Merck’s Lagevrio (molnupiravir) Missed Primary Endpoints in P-III Trial (MOVe-AHEAD) for Post-Exposure Prophylaxis to Prevent COVI...

Shots: The P-III trial (MOVe-AHEAD) evaluating Lagevrio (800mg) vs PBO in 1500 pat...

Novavax Initiates P-II Trial of COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Novavax Initiates P-II Trial of COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Shots: The company initiates the P-II trial, conducted in 2 parts evaluating the c...

Junshi Biosciences Reports P-III Clinical Trial Results of VV116 for Severe COVID-19

Junshi Biosciences Reports P-III Clinical Trial Results of VV116 for Severe COVID-19

Shots: The P-III trial results published in

Jiangsu Recbio Technology Reports P-II Study Results of Two-Component COVID-19 Vaccine ReCOV

Jiangsu Recbio Technology Reports P-II Study Results of Two-Component COVID-19 Vaccine ReCOV

Shots: The P-II study evaluating the immunogenicity & safety profile of recomb...

Image